Research
Research

Azacitidine Kills Leukemia Cells By Targeting RNA, Not DNA

By Everett Young ·

The finding suggests the drug stops leukemia cells before they can divide and spread

Researchers have discovered that azacitidine, a long-standing treatment for blood cancers, primarily acts on RNA rather than DNA. This finding reframes how the drug eliminates leukemia cells. The discovery emerged from detailed laboratory analysis of cellular responses to the medication. Azacitidine has treated high-risk myelodysplastic syndromes and acute myeloid leukemia for over twenty years. Scientists previously believed it worked by removing chemical tags from DNA to reactivate silenced genes. New evidence shows the drug's main mechanism involves RNA processing. This shift in understanding explains why the drug remains effective despite resistance patterns. The RNA Targeting Mechanism The research team examined how azacitidine interacts with cellular molecules at the molecular level. They found the drug binds to RNA structures, disrupting the production of proteins that help cancer cells survive. This RNA-focused action occurs earlier in the cellular lifecycle than previously thought.

The finding suggests the drug stops leukemia cells before they can divide and spread. Why Does This Change Treatment Strategies? Understanding the RNA mechanism opens new avenues for combination therapies. Doctors can now pair azacitidine with drugs that further disrupt RNA processing. This knowledge also helps predict which patients will respond best. Clinical trials may soon test these targeted combinations to improve survival rates. The discovery could lead to more precise dosing and patient selection. Oncologists can use RNA biomarkers to identify responders. As a result, treatment becomes more personalized and less trial-and-error. Frequently Asked Questions Does this change how azacitidine is prescribed today? Not immediately, but the RNA insight will guide future combination protocols. Clinicians may adjust dosing based on RNA biomarker profiles. Can this mechanism explain drug resistance? Yes. If resistance stems from altered RNA processing, new companion drugs can target that pathway directly.

How fast might new combination therapies reach patients? Clinical trials testing RNA-targeted combinations are expected to begin within the next two years.